Post by
colima on Apr 27, 2020 3:38pm
Just INFO
Ventilator patients are recovering with stem cell treatment Good day everyone, We are continuing our coverage of Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a specialty pharmaceutical company that develops and commercializes critical care products. Price at the time of our report $.81 per share We told you earlier this month that CTXR has signed an exclusive six-month option agreement to in-license a stem-cell therapy for ARDS from a subsidiary of Novellus, Inc., a privately held pre-clinical stage biotech company. The license from Novellus, Inc. is to develop their patented treatment for acute respiratory distress syndrome (ARDS). ARDS is the most common cause of respiratory failure and mortality in COVID-19 patients. There are no market estimates currently for an effectiveCovid 19 related ARDS cure. Novellus's patented process uses its exclusive non-immunogenic synthetic messenger ribonucleic acid (mRNA) molecules to create induced pluripotent stem cells (iPSCs) that, in turn, generate mesenchymal stem cells (MSCs) with superiorimmunomodulatory properties. MSCs have been shown to be safe in over 900 clinical trials and to be safe and effective in treating many inflammatory diseases, including ARDS. MSCs prevent and suppress cytokine storm, believed to be the cause of the severe inflammation of ARDS and now seen in COVID-19 patients.